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A B S T R A C T
A 26-year old woman presented for evaluation of extensive edema, erythema, sinus tract formation and
purulent drainage from the left lower extremity after trauma from a wooden object approximately three
months prior. Skin biopsies and blood cultures revealed Phaeoacremonium parasiticum consistent with a
diagnosis of phaeohyphomycosis. Despite hospitalization and initial treatment with several antifungals,
including voriconazole, her infection progressed. Surgical debridement with split thickness skin grafting
was performed. Subsequent clinical improvement allowed a transition from intravenous to oral
voriconazole and discharge home. Seven months post presentation she remained on oral voriconazole
with signiﬁcant improvement and no clinical evidence of recurrence. This case illustrates an approach to
management where aggressive debridement with split-thickness skin grafting and a prolonged course of
intravenous and oral antifungals resulted in a good long-term outcome for the patient.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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The genus Phaeoacremonium comprises dematiaceous molds
ﬁrst identiﬁed as etiologic agents of phaeohyphomycosis by Ajello
et al. in 1974 [1]. Phaeoacremonium species are primarily
environmental pathogens of woody plants, though some species
are known to cause human disease after cutaneous trauma
[1]. Cutaneous infection by Phaeoacremonium is most often
encountered and may lead to dissemination and fungemia,
particularly in immunocompromised patients [2]. Recent data
have suggested an increasing incidence of phaeohyphomycosis.
Cutaneous presentation can be varied and may include subcuta-
neous nodules, macules, papules, pustules, plaques, eschars and* Corresponding author at: University of Iowa Hospital and Clinics, 200 Hawkins
Drive, SW54 GH, Iowa City, IA 52242, United States. Tel.: +1 319 356 7740;
fax: +1 319 356 4600.
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identiﬁed from medical records at the University of Texas M.D.
Anderson Cancer Center, 38% had skin lesions and 33% of
39 patients died within three months of diagnosis [3]. Treatment
is often complex and includes prolonged use of intravenous and
oral antifungals and possibly surgical intervention. We report a
case of extensive phaeohyphomycosis secondary to Phaeoacremo-
nium parasiticum in an immunocompromised patient that was
successfully treated by a multidisciplinary team with antimicro-
bial and surgical interventions.
Case
A 26-year-old Hispanic woman presented from an outside
hospital for evaluation of left lower extremity swelling, erythema,
edema, and purulent drainage of three months’ duration after
trauma to her left leg from a wooden object. Her past medical
history was signiﬁcant for systemic lupus erythematosus (SLE)
with stage IV nephritis for which she was treated with prednisonender the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. Examination revealed left lower extremity erythema and edema along with papules, pustules and nodules extending from the left dorsal foot to the left medial thigh
(A). Closer examination demonstrated tender papules, some with overlying crust (B).
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at presentation to our hospital. Initially, she was admitted to a local
hospital and treated for possible cellulitis with vancomycin and
piperacillin/tazobactam and later with numerous antifungals
including itraconazole, ﬂuconazole, voriconazole and amphoteri-
cin B for approximately one month without improvement.
Physical examination revealed a well appearing, afebrile
Hispanic woman in no acute distress. From her left dorsal foot
to her left medial thigh there was marked woody induration with
numerous warm and tender papules, nodules, and several pustules
coalescing into larger plaques with sinus tract formation (Fig. 1A
and B). Several areas with purulent drainage and dark brown crust
were identiﬁed. The left leg was signiﬁcantly larger and more
edematous than the right leg. There was no inguinal lymphade-
nopathy. Given the patient’s immunosuppression, an infectious
process was suspected, encompassing clinical concern for fungi
and mycobacteria. Skin punch biopsies were therefore taken from
the left lower extremity for histopathologic evaluation and culture.
Histopathologic evaluation revealed a dense acute inﬂammatory
inﬁltrate composed of numerous palisading histiocytic granulo-
mas with interspersed giant cells, central neutrophilic micro-
abscesses and lymphocytes extending from the superﬁcial to the
deep dermis. Periodic acid-Schiff (PAS) and Grocott Methenamine
Silver (GMS) staining revealed numerous septate, hyaline hyphae
with acute angle branching consistent with phaeohyphomycosis
(Fig. 3A and B).
The patient was evaluated by a multidisciplinary team
including infectious disease, dermatology, rheumatology, internal
medicine and burn surgery. Magnetic resonance imaging of the left
lower extremity and brain along with computed tomography of the
chest did not reveal evidence of disseminated disease. Aerobic and
anaerobic bacterial and fungal blood and skin cultures were
performed and demonstrated Phaeoacremonium spp.
Culture of biopsy material revealed small white colonies on
Remel potato dextrose agar at 25 8C within 72 h. In slide culture onFig. 2. Physical examination of the left lower leg, two days post-debridement (A). Left l
6 months after follow up (D–E).cornmeal agar at 25 8C colonies were initially velvety and white-
gray and developed gray-brown pigment and clusters of brown
aerial hyphae at one week (Fig. 4A and B). A lactophenol cotton
blue mount revealed pigmented septate hyphae with brown,
cylindrical, slightly tapered conidiophores with clusters of oblong,
hyaline conidia consistent with Phaeoacremonium species (Fig. 4C).
Isolate identiﬁcation was obtained by D2 large subunit (LSU)
ribosomal DNA fungal sequencing [4] at the State Hygienic
Laboratory at the University of Iowa. Related sequences deposited
in the National Center for Biotechnology Information (NCBI)
GenBank [5] were located using BLAST [6]. P. parasiticum (NCBI
accession no. HE792808) was identiﬁed as 99.6% identical to the
patient isolate.
Antifungal susceptibility testing was performed at Mayo
Medical Laboratories (Rochester, MN) and the University of Texas
Health Science Center (San Antonio, TX) utilizing the Clinical
Laboratory Standards Institute (CLSI) broth microdilution method
M38-A2 [7]. Minimum inhibitory concentration (MIC) endpoints,
deﬁned as the lowest drug concentration that prevented discern-
ible growth, were determined at 48 and 72 h. The MICs of
amphotericin B, voriconazole, ﬂuconazole, and terbinaﬁne against
the patient’s isolates of P. parasiticum are shown in Table 1. Drug
interactions (synergy) studies were performed by the University of
Texas Health Science Center using a checkerboard microdilution
method [7,8] and testing parameters as described in CLSI M38-A2
and are shown in Table 2.
Surgical debridement was recommended given the lack of
improvement with intravenous antifungals. Her immunosuppres-
sive therapy was temporarily held, and she underwent extensive
surgical debridement followed by split thickness skin grafting
(Fig. 2A and B). She was continued on voriconazole at 200 mg orally
twice daily with terbinaﬁne 500 mg three times daily; however,
terbinaﬁne was decreased to 500 mg twice daily and later
discontinued due to leukopenia and absence of synergistic activity
with laboratory testing. Treatment for SLE was later resumed withower extremity after placement of split thickness skin graft (B), 3 months (C) and
Fig. 3. Histologic sections of the punch biopsy show a dense inﬂammatory inﬁltrate and numerous granulomas; staining with PAS (A) and GMS stains (B) revealed numerous
septate, hyaline hyphae with acute angle branching. Reproductive structures were not identiﬁed.
Fig. 4. Pictured are colonies (superior (A) and inferior (B) aspects of culture plate shown) with moderate to slow growth in potato dextrose agar at 25 8C; colonies are
low-lying, velvety, and white-gray to brown. Lactophenol cotton blue stain following growth in cornmeal agar for slide culture at 1 week (C) reveals phialides bearing apical
clusters of cylindrical, hyaline conidia and brown septate hyphae consistent with Phaeoacremonium species.
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Table 1
In vitro susceptibilities of Phaeoacremonium parasiticum isolate.
Drug Result (mg/ml) CLSI M38-A2 interpretation
VORI 0.5 No established guidelines
TERB 0.5 No established guidelines
AMB 1.0 No established guidelines
FLU >64 No established guidelines
VORI, voriconazole; TERB, terbinaﬁne; AMB, amphotericin B; FLU, ﬂuconazole. MIC
endpoints for all drugs are deﬁned as lowest drug concentrations that prevent
discernable growth (optically clear) compared to drug-free controls.
R.I. El-Herte et al. / IDCases 1 (2014) 84–88 87prednisone 5 mg daily and hydroxychloroquine 300 mg daily. At
follow up seven months later, the patient was doing well with no
clinical evidence of recurrence (Fig. 2C–E).
Discussion
P. parasiticum is a ubiquitous dematiaceous mold that rarely
causes human infection. This mold was initially reported in 1974 as
Phialophora and subsequently associated with the Phaeoacremo-
nium genus by Crous et al. in 1996 [9]. Phaeoacremonium species
reported to cause human infection have included P. parasiticum,
P. rubrigenum, P. alvesii, P. krajdenii, P. amstelodamense, P. griseorubrum,
P. tardicrescens, and P. venezuelense [2].
Patients presenting with Phaeoacremonium infection often have
conditions rendering them immunocompromised including he-
matologic malignancies in the setting of chemotherapy, stem cell
transplantation, rheumatoid arthritis treated with inﬂiximab, or
adult Still’s disease managed with oral prednisolone [3,9–11]. The
reported increase in dematiaceous mold infections may be related
to the increasing size of the immunosuppressed population.
However, there also have been reports of Phaeoacremonium
infection in healthy adults [2].
Clinically, patients often present after trauma to the cutaneous
tissue of the lower extremity, resulting in local inoculation. This
may result in nodules, cysts, abscess, or eumycetoma characterized
by edema, sinus tract formation, and purulent drainage with grain
formation [10]. Possible complications include fungemia, central
nervous systemic infection including brain abscess, endophthal-
mitis, osteomyelitis, arthritis, cavitary lung lesions, airway
colonization, sinusitis and infective endocarditis [3,12].
Antifungal regimens utilized in the management of phaeohy-
phomycosis due to Phaeoacremonium species vary as optimal
treatment has not yet been clearly deﬁned; however, good
outcomes have been associated with itraconazole, amphotericin
B, 5-ﬂuorocytosine, voriconazole, terbinaﬁne, and surgical de-
bridement [12–14]. Azoles, in particular, have been reported to
yield good results. Although dematiaceous molds have been
increasingly implicated as signiﬁcant human pathogens, particu-
larly in immunosuppressed individuals, there is little data on in
vitro antifungal susceptibility and the efﬁcacy of combination drug
therapy [13]. An analysis of 381 isolates of ﬁlamentous fungi,
including eight isolates of P. parasiticum, reported favorable in vitro
activity of voriconizole against P. parasiticum (MIC range 0.125–
2 mg/ml, mean 0.55 mg/ml) while the MICs of amphotericin B
(range 1–16 mg/ml, mean 3.08 mg/ml) and itraconazole (range
0.25–32 mg/ml, mean 6.17 mg/ml) were less favorable [15]. Cur-
rently, MIC susceptibility breakpoints have not been establishedTable 2
Synergy of voriconazole and terbinaﬁne against Phaeoacremonium parasiticum
isolate.
Drugs Result (mg/ml) Interpretation
VORI + TERB 0.125 + 0.25 Indifferent
VORI, voriconazole; TERB, terbinaﬁne.and there is no data correlating MICs with clinical outcome so MIC
data should be interpreted with caution [14].
Combination drug therapy has been showed to be effective in
the treatment of certain dematiaceous fungal infections. A
synergistic reduction in antifungal MICs may be shown with the
addition of a second drug that reﬂects enhanced antifungal activity
in vivo. In vitro synergy has been reported between terbinaﬁne and
both amphotericin B and azoles. A recent study by Biancalana et al.
investigated the synergistic activity of terbinaﬁne in combination
with itraconazole, voriconazole, and amphotericin B in the
treatment of various dematiaceous fungal infections (not including
Phaeoacremonium species). Outcomes showed 100% synergism
(29 of 29 isolates) for terbinaﬁne in combination with voricona-
zole, 96.5% synergism for terbinaﬁne in combination with
amphotericin B, and 75.9% synergism for terbinaﬁne in combina-
tion with itraconazole. No antagonism was identiﬁed [13]. Howev-
er, as in this case, indifferent synergistic results have also been
reported for some dematiaceous fungi [16]. Further research is
needed to standardize the roles of combination drug therapy,
surgical debridement and other management strategies in patients
with phaeohyphomycosis due to P. parasiticum and other
dematiaceous molds.
Herein, we report a rare and extensive case of phaeohypho-
mycosis secondary to Phaeoacremonium parasiticum in an immu-
nocompromised patient. Clinical and therapeutic success required
withdrawal of immunosuppressive therapy, extensive surgical
debridement and skin grafting in parallel with a prolonged course
of antifungal therapy. Microbiologic identiﬁcation and suscepti-
bility testing were imperative for appropriate antifungal selection
as empiric antifungal regimens for phaeohyphomycosis are not
currently well deﬁned [13].
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